Prospective, Multicenter, Observational Study to Evaluate Physical Activity, Bleeding Events, Quality of Daily Life, and Safety in Patients with Congenital Hemophilia A Without FVIII Inhibitors Under Emicizumab Prophylaxis
Not Applicable
- Conditions
- Congenital hemophilia A
- Registration Number
- JPRN-UMIN000037448
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Inherited or acquired bleeding disorder other than congenital hemophilia A. (2) Undergoing immune tolerance induction (ITI) at the time of enrollment. (3) Previous use of emicizumab. (4) Any other reason that, in the judgment of the investigator, would render the patient unsuitable for study participation.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method